Guerini AE et al., 2019-08-31: A wide literature review of mebendazole as an anticancer candidate that summarises mechanism, preclinical and clinical evidence and closes by calling for clinical trials. It also states plainly that mebendazole is a synthetic benzimidazole, and notes that its low price discourages industry funding.
Mebendazole is a synthetic benzimidazole effective against a broad spectrum of intestinal helminthiasis.
Section 2
Guerini AE et al., 2019-08-31: A wide literature review of mebendazole as an anticancer candidate that summarises mechanism, preclinical and clinical evidence and closes by calling for clinical trials. It also states plainly that mebendazole is a synthetic benzimidazole, and notes that its low price discourages industry funding. Study type: narrative/systematic-style literature review (last literature update 13 August 2019 as stated in the text). Country: Italy. No subjects. Funding statement as printed: 'This research received no external funding.' Conflicts: 'The authors declare no conflict of interest.' Also states in the same paper that mebendazole's 'low cost is a double-edged sword, as the lack of expected profit might discourage funding from pharmaceutical companies seeking a return on investments' – recorded as the authors' words, relevant to why repurposing is academically driven. Study type: review.
